KISIMA-02 vaccine-based immunotherapy for patients with mutated pancreatic cancer

2022-501854-12-00 Protocol KISIMA-02 Human pharmacology (Phase I) - First administration to humans Not authorised

Status Not authorised · 1 EU/EEA countries · 4 sites · Protocol KISIMA-02

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Not authorised
Participants planned 85
Countries 1
Sites 4

KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma

Key facts

Sponsor
Amal Therapeutics S.A.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Decision date (initial)
2023-06-06
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma

VersionLevelCodeTermSystem organ class
21.0 LLT 10033599 Pancreatic adenocarcinoma metastatic 10029104
21.0 LLT 10033602 Pancreatic adenocarcinoma resectable 10029104
21.0 LLT 10033600 Pancreatic adenocarcinoma non-resectable 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Amal Therapeutics S.A.

Sponsor organisation
Amal Therapeutics S.A.
Address
Avenue De La Roseraie 64
City
Geneva
Postcode
1205
Country
Switzerland

Scientific contact point

Organisation
Amal Therapeutics S.A.
Contact name
Cristina Riccadonna

Public contact point

Organisation
Amal Therapeutics S.A.
Contact name
Cristina Riccadonna

Locations

1 EU/EEA country · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Not authorised 15 4
Rest of world
United States, Switzerland
70

Investigational sites

Spain

4 sites · Not authorised
Hospital Universitario Fundacion Jimenez Diaz
Oncology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital General Universitario Gregorio Maranon
Oncology, Calle Del Doctor Esquerdo 46, 28009, Madrid
Hospital Universitari Vall D Hebron
Oncology, Edificio Materno-Infantil, Passeig De La Vall D'hebron 119-129, Barcelona
Hospital Universitario Hm Sanchinarro
Oncology, Calle Ona 10, 28050, Madrid

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-03-01 Spain Not acceptable
2023-06-06
2023-06-06